Novartis stock trades steady as recent earnings highlight growth in key therapies

Novartis stock reflects steady sentiment after recent quarterly figures showed higher core operating income and expanding margins on the back of strong demand for innovative medicines.

Novartis stock is underpinned by recent earnings that showed the Swiss pharmaceutical group (ISIN CH0012005267) increasing net sales and core operating income on the back of its innovative medicines portfolio in 2024. In the latest reported quarter, Novartis generated net sales of around $11.5 billion, with growth compared with the prior-year period driven by key oncology and immunology therapies. Core operating income for the same quarter rose to approximately $4.0 billion, reflecting both higher volumes and an improved product mix. The figures maintain investor attention on how efficiently Novartis converts its pipeline into commercial success.

Core income rises with margin expansion

In its most recent quarterly update in 2024, Novartis reported that net sales increased by roughly high single-digit percentages compared with the same period in 2023, translating into around $11.5 billion in revenue. Core operating income in that quarter climbed to close to $4.0 billion, up from about $3.6 billion a year earlier, signaling an improvement of around 10% year on year. This expansion in core operating income reflects higher gross margins from growth in patented medicines and continued cost discipline in supporting functions.

Management highlighted that the core operating margin for the group in that quarter moved closer to the mid-thirties in percentage terms, compared with the low-thirties in the prior year. That margin improvement underscores how the company’s shift toward higher-value therapies, particularly in oncology and immunology, is translating into stronger profitability. For investors, the combination of mid-to-high single-digit net sales growth and double-digit core operating income growth is a key signal of operating leverage in the business model.

Net sales around $45 billion for full year

For the full year 2023, Novartis reported net sales of roughly $45 billion, marking a modest increase compared with the approximately $44 billion generated in 2022. The increase was driven by the Innovative Medicines segment, which offset the impact of generic competition on certain mature products. Core operating income for 2023 was in the region of $15 billion, up from around $14 billion in 2022, indicating a mid-single-digit percentage increase in profitability across the group. The annual numbers confirm that the quarterly trend of rising margins is visible over a longer period as well.

On a segment basis, the Innovative Medicines division contributed the majority of group revenue, with annual net sales of more than $38 billion in 2023. Within this division, oncology therapies accounted for over $15 billion of sales, with growth compared with the prior year supported by demand for targeted treatments and immunotherapy-based approaches. The remaining revenues stemmed from cardiovascular, ophthalmology, neuroscience, and other specialty care therapies. For investors evaluating Novartis stock, the persistence of double-digit sales contributions from oncology is a central element of the long-term equity story.

Gainers from Cosentyx and Entresto

Among individual products, therapies such as Cosentyx and Entresto have played a notable role in supporting the recent revenue trajectory. Cosentyx, a biologic treatment for psoriasis, psoriatic arthritis, and other inflammatory conditions, generated annual sales of around $4.5 billion in 2023, up from roughly $4.0 billion in 2022, representing growth of about 12%. Entresto, used for certain forms of chronic heart failure, delivered annual net sales of close to $5.0 billion in 2023, compared with approximately $4.2 billion a year earlier, marking growth of around 19%. These products have become central pillars of the Innovative Medicines portfolio.

The growth of Cosentyx and Entresto illustrates how Novartis is benefiting from significant demand in immunology and cardiovascular care. Higher adoption of these treatments in major markets such as the United States and Europe has helped compensate for the erosion of sales from older brands facing generic competition. The company has emphasized ongoing efforts to secure additional indications and label expansions, which could further support sales over the coming years. In the nearer term, the demonstrated double-digit revenue growth of these therapies offers investors tangible evidence of commercial strength.

Pipeline and R&D investment near $9 billion

Novartis continues to invest heavily in research and development to sustain its pipeline. In 2023, total R&D expenditure amounted to approximately $9 billion, representing around 20% of net sales and broadly in line with the $9 billion invested in 2022. The company's pipeline includes more than one hundred projects in clinical development, with a mix of early-stage and late-stage candidates in oncology, immunology, cardiovascular disease, neuroscience, and ophthalmology. Several phase III programs target high-prevalence conditions, potentially giving Novartis access to multi-billion-dollar peak sales opportunities if successfully approved.

Over the past five years, Novartis has progressively shifted its R&D focus toward precision medicine and advanced therapies, including cell and gene treatments. This strategic emphasis aims to build differentiated assets that can command premium pricing and drive long-term revenue growth. While late-stage failures remain a natural risk in pharmaceuticals, the company's diversified pipeline helps mitigate concentration risk. For Novartis stock, the balance between ongoing cash generation from established drugs and future growth from pipeline assets is a core theme in equity research and valuation work.

Balance sheet and free cash flow above $13 billion

On the financial side, Novartis maintains a solid balance sheet and strong cash generation. In 2023, free cash flow reached around $13 billion, slightly above the approximately $12.5 billion reported in 2022, offering the company significant flexibility for dividends, share repurchases, and targeted acquisitions. Net debt at year-end 2023 was in the range of $21 billion, compared with around $22 billion the year before, reflecting a gradual improvement in leverage as cash flow outpaced new borrowing. The ratio of net debt to core EBITDA remained at levels consistent with a high investment-grade credit profile.

The company has complemented organic growth with selective portfolio optimization, including divestments of non-core assets and bolt-on acquisitions in priority therapeutic areas. In recent years, divestments have helped sharpen strategic focus on Innovative Medicines while freeing capital for higher-return investments. For shareholders, the combination of sustained free cash flow, modest leverage, and disciplined capital allocation is an important factor in assessing the resilience of Novartis stock across different market environments.

Dividend policy and shareholder returns

Novartis has a track record of returning cash to shareholders through a progressive dividend policy. For the 2023 financial year, the company proposed a dividend of around CHF 3.30 per share, up from CHF 3.20 for 2022, reflecting a modest increase of about 3%. Over the past decade, Novartis has consistently maintained or increased its dividend, making the stock attractive for income-focused investors. The payout ratio, measured against core earnings per share, has generally remained in a range supportive of continued reinvestment in the business.

Alongside dividends, Novartis has occasionally used share repurchases to manage its capital structure and offset the dilutive impact of employee stock programs. These buybacks have been sized within the limits of free cash flow and balance sheet strength. In periods of market volatility, the consistency of the dividend and disciplined buyback activity can help support the valuation of Novartis stock, even when sentiment toward the broader pharmaceutical sector fluctuates.

Risks from competition and regulation

Despite the positive earnings profile, Novartis faces the familiar risks of competitive pressures and regulatory changes. Biosimilar and generic competition can erode revenues from older brands, requiring continuous innovation and portfolio renewal. Regulatory agencies in major markets are also focusing on pricing and market access, which can influence margins, especially for therapies that face cost-effectiveness scrutiny. In addition, litigation and compliance topics are a recurring feature in global pharma and can occasionally lead to settlements or operational changes.

Novartis addresses these risks through a combination of pipeline replenishment, geographical diversification, and engagement with regulators and payers. The company's exposure to a broad range of therapeutic areas, including oncology, cardiovascular disease, and immunology, reduces dependence on any single franchise. For Novartis stock holders, understanding the balance between product lifecycle risks and pipeline opportunities is a central part of assessing the long-term risk-reward profile of the investment.

Cosentyx and other key products

Cosentyx stands out as one of Novartis's flagship products in immunology. As of 2023, annual sales of around $4.5 billion illustrate the scale of the franchise, which spans multiple indications, including psoriasis and psoriatic arthritis. By pursuing additional indications and improving patient adherence through support programs, Novartis aims to sustain growth in this franchise. Beyond Cosentyx, other key products such as Entresto, Jakavi, and Kisqali contribute to a diversified revenue base across cardiovascular care and oncology.

Novartis continues to launch new products and extend existing labels to keep its portfolio competitive. The company's long-term ambition is to maintain a pipeline that can support mid-single-digit or better net sales growth, complemented by margin expansion from efficiency initiatives. For patients, the breadth of therapies means wider access to treatments for serious conditions; for investors, the same breadth underpins the thesis that Novartis stock can capture value from multiple medical advances over time.

Novartis stock and current valuation context

In equity markets, Novartis stock trades on the SIX Swiss Exchange under the symbol NOVN and is also represented on other European trading venues. As of a recent trading day in 2024, Novartis shares changed hands around CHF 90, positioning the stock in the middle of a 52-week trading range roughly between CHF 80 and CHF 100. This price level corresponds to a market capitalization in the area of CHF 190 billion, reflecting the company's status as one of Europe's largest healthcare groups. The valuation metrics, including price-to-earnings and enterprise-value-to-EBITDA ratios, place Novartis within the typical range for large-cap global pharmaceuticals.

For investors, the stock's current valuation takes into account the combination of stable cash flows from established therapies, growth from newer products such as Cosentyx and Entresto, and the potential of the development pipeline. While short-term price moves can be influenced by macroeconomic factors and sector rotation, the fundamental drivers of Novartis stock remain earnings growth, margin resilience, pipeline progress, and capital allocation discipline.

Novartis at a glance

• Company: Novartis AG
• ISIN: CH0012005267
• Ticker: SIX: NOVN
• Trading venue: SIX Swiss Exchange
• Price (as of 1 June 2024, 16:30 CET): 90.00 CHF
• Market capitalization: 190 billion CHF (as of 1 June 2024)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: SMI
• Next earnings date: 24 July 2024